Oncolytic poliovirus against malignant glioma

Future Virology

Volumn 6, Issue 9, 2011, Pages 1045-1058

  Goetz, Christian ^a   Dobrikova, Elena ^a   Shveygert, Mayya ^a   Dobrikov, Mikhail ^a   Gromeier, Matthias ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

elF4E; elF4G; Erk; glloblastoma; IRES; Mnk1; Necl 5; PKC ; pollovirus; translation

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; ONCOLYTIC POLIOMYELITIS VIRUS; ONCOLYTIC VIRUS; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER THERAPY; CELL SPECIFICITY; CELL STRAIN HEK293; CYTOTOXICITY; ENZYME INHIBITION; GLIOBLASTOMA; HUMAN; NONHUMAN; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION; VIRAL TROPISM; VIRUS GENE; VIRUS GENOME;

POLIOVIRUS;

EID: 80052996500     PISSN: 17460794     EISSN: 17460808     Source Type: Journal    
DOI: 10.2217/fvl.11.76     Document Type: Article

References (77)

1. Bluming AZ, Ziegler JL. Regression of Burkitt's lymphoma in association with measles infection. Lancet 2(7715), 105-106 (1971)
2. De Pace N. Sulla scomparsa di un enorme cancro vegetante del callo dell'utero senze cura chirurgica. Ginecologia 9, 82-88 (1912)
3. Coffey MC, Strong JE, Forsyth PA, Lee PW. Reovirus therapy of tumors with activated Ras pathway. Science 282(5392), 1332-1334 (1998) (Pubitemid 28524498)
4. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med. 6(7), 821-825 (2000) (Pubitemid 30469434)
5. Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252(5007), 854-856 (1991) (Pubitemid 121000529)
6. Liu BL, Robinson M, Han ZQ, et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther. 10(4), 292-303 (2003) (Pubitemid 36305598)
7. Senzer NN, Kaufman HL, Amatruda T, et al. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J. Clin. Oncol. 27(34), 5763-5771 (2009)
8. Kaufman HL, Kim DW, DeRaffele G, Mitcham J, Coffin RS, Kim-Schulze S. Local and distant immunity induced by intralesional vaccination with an oncolytic herpes virus encoding GM-CSF in patients with stage IIIc and IV melanoma. Ann. Surg. Oncol. 17(3), 718-730 (2010)
9. Gustin KE, Sarnow P. Effects of poliovirus infection on nucleo-cytoplasmic trafficking and nuclear pore complex composition. EMBO J. 20(1-2), 240-249 (2001) (Pubitemid 32099120)
10. Etchison D, Milburn SC, Edery I, Sonenberg N, Hershey JW. Inhibition of HeLa cell protein synthesis following poliovirus infection correlates with the proteolysis of a 220,000-dalton polypeptide associated with eucaryotic initiation factor 3 and a cap binding protein complex. J. Biol. Chem. 257(24), 14806-14810 (1982) (Pubitemid 13159573)
11. Goldstaub D, Gradi A, Bercovitch Z, et al. Poliovirus 2A protease induces apoptotic cell death. Mol. Cell. Biol. 20(4), 1271-1277 (2000) (Pubitemid 30069248)
12. Toyoda H, Yin J, Mueller S, Wimmer E, Cello J. Oncolytic treatment and cure of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res. 67(6), 2857-2864 (2007) (Pubitemid 46548976)
13. Toyoda H, Wimmer E, Cello J. Oncolytic poliovirus therapy and immunization with poliovirus-infected cell lysate induces potent antitumor immunity against neuroblastoma in vivo. Int. J. Oncol. 38(1), 81-87 (2011)
14. Menotti L, Cerretani A, Campadelli-Fiume G. A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors. J. Virol. 80(11), 5531-5539 (2006)
15. Mathis JM, Stoff-Khalili MA, Curiel DT. Oncolytic adenoviruses - selective retargeting to tumor cells. Oncogene 24(52), 7775-7791 (2005) (Pubitemid 41670679)
16. Allen C, Vongpunsawad S, Nakamura T, et al. Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res. 66(24), 11840-11850 (2006) (Pubitemid 46094196)
17. Takai Y, Miyoshi J, Ikeda W, Ogita H. Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat. Rev. Mol. Cell. Biol. 9(8), 603-615 (2008) (Pubitemid 352032927)
18. Nobis P, Zibirre R, Meyer G, Kǔhne J, Warnecke G, Koch G. Production of a monoclonal antibody against an epitope on HeLa cells that is the functional poliovirus binding site. J. Gen. Virol. 66(Pt 12), 2563-2569 (1985) (Pubitemid 16180019)
19. Mendelsohn CL, Wimmer E, Racaniello VR. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56(5), 855-865 (1989) (Pubitemid 19082521)
20. Ren RB, Costantini F, Gorgacz EJ, Lee JJ, Racaniello VR. Transgenic mice expressing a human poliovirus receptor: a new model for poliomyelitis. Cell 63(2), 353-362 (1990)
21. Koike S, Taya C, Kurata T, et al. Transgenic mice susceptible to poliovirus. Proc. Natl Acad. Sci. USA 88(3), 951-955 (1991) (Pubitemid 21916142)
22. Iwasaki A, Welker R, Mueller S, Linehan M, Nomoto A, Wimmer E. Immunofluorescence analysis of poliovirus receptor expression in Peyer's patches of humans, primates, and CD155 transgenic mice: implications for poliovirus infection. J. Infect. Dis. 186(5), 585-592 (2002) (Pubitemid 34925529)
23. Koike S, Aoki J, Nomoto A. Transgenic mouse for the study of poliovirus pathogenicity. In:Cellular Receptors for Animal Viruses. Wimmer E (Ed). Cold Spring Harbor Laboratory Press, NY, USA, 463-480 (1994)
24. Geraghty RJ, Krummenacher C, Cohen GH, Eisenberg RJ, Spear PG. Entry of alphaherpesviruses mediated by poliovirus receptor-related protein 1 and poliovirus receptor. Science 280(5369), 1618-1620 (1998) (Pubitemid 28277708)
25. Gromeier M, Solecki D, Patel DD, Wimmer E. Expression of the human poliovirus receptor/CD155 gene during development of the central nervous system: implications for the pathogenesis of poliomyelitis. Virology 273(2), 248-257 (2000) (Pubitemid 30641366)
26. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH, Wimmer E. Intergeneric poliovirus recombinants for the treatment of malignant glioma. Proc. Natl Acad. Sci. USA 97(12), 6803-6808 (2000) (Pubitemid 30412795)
27. Merrill MK, Bernhardt G, Sampson JH, Wikstrand CJ, Bigner DD, Gromeier M. Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro Oncol. 6(3), 208-217 (2004) (Pubitemid 39136504)
28. Sloan KE, Stewart JK, Treloar AF, Matthews RT, Jay DG. CD155/PVR enhances glioma cell dispersal by regulating adhesion signaling and focal adhesion dynamics. Cancer Res. 65(23), 10930-10937 (2005) (Pubitemid 41713361)
29. Sloan KE, Eustace BK, Stewart JK, et al. CD155/PVR plays a key role in cell motility during tumor cell invasion and migration. BMC Cancer 4, 73 (2004)
30. Masson D, Jarry A, Baury B, et al. Overexpression of the CD155 gene in human colorectal carcinoma. Gut 49(2), 236-240 (2001) (Pubitemid 32675118)
31. Ochiai H, Moore SA, Archer GE, et al. Treatment of intracerebral neoplasia and neoplastic meningitis with regional delivery of oncolytic recombinant poliovirus. Clin. Cancer Res. 10(14), 4831-4838 (2004) (Pubitemid 38955537)
32. Nakai R, Maniwa Y, Tanaka Y, et al. Overexpression of Necl-5 correlates with unfavorable prognosis in patients with lung adenocarcinoma. Cancer Sci. 101(5), 1326-1330 (2010)
33. Erickson BM, Thompson NL, Hixson DC. Tightly regulated induction of the adhesion molecule Necl-5/CD155 during rat liver regeneration and acute liver injury. Hepatology 43(2), 325-334 (2006)
34. Solecki D, Schwarz S, Wimmer E, Lipp M, Bernhardt G. The promoters for human and monkey poliovirus receptors. Requirements for basic and cell type-specific activity. J. Biol. Chem. 272(9), 5579-5586 (1997) (Pubitemid 27102382)
35. Solecki D, Bernhardt G, Lipp M, Wimmer E. Identification of a nuclear respiratory factor-1 binding site within the core promoter of the human polio virus receptor/CD155 gene. J. Biol. Chem. 275(17), 12453-12462 (2000) (Pubitemid 30241387)
36. Solecki DJ, Gromeier M, Mueller S, Bernhardt G, Wimmer E. Expression of the human poliovirus receptor/CD155 gene is activated by sonic hedgehog. J. Biol. Chem. 277(28), 25697-25702 (2002) (Pubitemid 34951888)
37. Solecki D, Wimmer E, Lipp M, Bernhardt G. Identification and characterization of the cis-acting elements of the human CD155 gene core promoter. J. Biol. Chem. 274(3), 1791-1800 (1999)
38. Castriconi R, Daga A, Dondero A, et al. NK cells recognize and kill human glioblastoma cells with stem cell-like properties. J. Immunol. 182(6), 3530-3539 (2009)
39. Toyoda H, Nicklin MJ, Murray MG, et al. A second virus-encoded proteinase involved in proteolytic processing of poliovirus polyprotein. Cell 45(5), 761-770 (1986)
40. Lloyd RE. Translational control by viral proteinases. Virus Res. 119(1), 76-88 (2006) (Pubitemid 43765974)
41. Dobrikova EY, Grisham RN, Kaiser C, Lin J, Gromeier M. Competitive translation efficiency at the picornavirus type 1 internal ribosome entry site facilitated by viral cis and trans factors. J. Virol. 80(7), 3310-3321 (2006)
42. Sonenberg N, Morgan MA, Merrick WC, Shatkin AJ. A polypeptide in eukaryotic initiation factors that crosslinks specifically to the 5′-terminal cap in mRNA. Proc. Natl Acad. Sci. USA 75(10), 4843-4847 (1978) (Pubitemid 9048631)
43. Nomoto A, Lee YF, Wimmer E. The 5′ end of poliovirus mRNA is not capped with m7G(5′)ppp(5′)Np. Proc. Natl Acad. Sci. USA 73(2), 375-380 (1976)
44. Pelletier J, Sonenberg N. Internal initiation of translation of eukaryotic mRNA directed by a sequence derived from poliovirus RNA. Nature 334(6180), 320-325 (1988)
45. Jang SK, Kräusslich HG, Nicklin MJ, Duke GM, Palmenberg AC, Wimmer E. A segment of the 5′ nontranslated region of encephalomyocarditis virus RNA directs internal entry of ribosomes during in vitro translation. J. Virol. 62(8), 2636-2643 (1988)
46. de Breyne S, Yu Y, Unbehaun A, Pestova TV, Hellen CU. Direct functional interaction of initiation factor eIF4G with type 1 internal ribosomal entry sites. Proc. Natl Acad. Sci. USA 106(23), 9197-9202 (2009)
47. Gromeier M, Alexander L, Wimmer E. Internal ribosomal entry site substitution eliminates neurovirulence in intergeneric poliovirus recombinants. Proc. Natl Acad. Sci. USA 93(6), 2370-2375 (1996) (Pubitemid 26104357)
48. Gromeier M, Bossert B, Arita M, Nomoto A, Wimmer E. Dual stem loops within the poliovirus internal ribosomal entry site control neurovirulence. J. Virol. 73(2), 958-964 (1999) (Pubitemid 29036746)
49. Campbell SA, Lin J, Dobrikova EY, Gromeier M. Genetic determinants of cell type-specific poliovirus propagation in HEK 293 cells. J. Virol. 79(10), 6281-6290 (2005) (Pubitemid 40617232)
50. Wimmer E, Hellen CU, Cao X. Genetics of poliovirus. Annu. Rev. Genet. 27, 353-436 (1993) (Pubitemid 24011358)
51. Horie H, Miyazawa M, Ota Y. Analysis of the accumulation of mutants in Sabin attenuated polio vaccine viruses passaged in Vero cells. Vaccine 19(11-12), 1456-1459 (2001) (Pubitemid 32332730)
52. Hofer F, Gruenberger M, Kowalski H, et al. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proc. Natl Acad. Sci. USA 91(5), 1839-1842 (1994) (Pubitemid 24080301)
53. Couch RB. Rhinoviruses. In:Fields Virology. Knipe DM, Howley PM (Eds). Lippincott Williams and Wilkins, PA, USA, 777-797 (2001)
54. Wang ES, Dobrikova E, Goetz C, Dufresne AT, Gromeier M. Adaptation of an ICAM-1 tropic enterovirus to the mouse respiratory tract. J. Virol. 85(11), 5606-5617 (2011)
55. Dufresne AT, Gromeier M. A nonpolio enterovirus with respiratory tropism causes poliomyelitis in intercellular adhesion molecule 1 transgenic mice. Proc. Natl Acad. Sci. USA 101(37), 13636-13641 (2004) (Pubitemid 39238455)
56. Dobrikova EY, Broadt T, Poiley-Nelson J, et al. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. Mol. Ther. 16(11), 1865-1872 (2008)
57. Merrill MK, Dobrikova EY, Gromeier M. Cell-type-specific repression of internal ribosome entry site activity by double-stranded RNA-binding protein 76. J. Virol. 80(7), 3147-3156 (2006)
58. Merrill MK, Gromeier M. The double-stranded RNA binding protein 76:NF45 heterodimer inhibits translation initiation at the Rhinovirus type 2 internal ribosome entry site. J. Virol. 80(14), 6936-6942 (2006) (Pubitemid 44025192)
59. Harashima A, Guettouche T, Barber GN. Phosphorylation of the NFAR proteins by the dsRNA-dependent protein kinase PKR constitutes a novel mechanism of translational regulation and cellular defense. Genes Dev. 24(23), 2640-2653 (2010)
60. Neplioueva V, Dobrikova EY, Mukherjee N, Keene JD, Gromeier M. Tissue type-specific expression of the dsRNA-binding protein 76 and genome-wide elucidation of its target mRNAs. PLoS One 5(7), E11710 (2010)
61. Goetz C, Everson RG, Zhang LC, Gromeier M. MAPK signal-integrating kinase controls cap-independent translation and cell type-specific cytotoxicity of an oncolytic poliovirus. Mol. Ther. 18(11), 1937-1946 (2010)
62. Yang X, Chen E, Jiang H, et al. Evaluation of IRES-mediated, cell-type-specific cytotoxicity of poliovirus using a colorimetric cell proliferation assay. J. Virol. Methods 155(1), 44-54 (2009)
63. Pyronnet S, Imataka H, Gingras AC, Fukunaga R, Hunter T, Sonenberg N. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E. EMBO J. 18(1), 270-279 (1999) (Pubitemid 29005042)
64. Shveygert M, Kaiser C, Bradrick SS, Gromeier M. Regulation of eIF4E phosphorylation by MAPK occurs through modulation of Mnk1-eIF4G interaction. Mol. Cell. Biol. 30(21), 5160-5167 (2010)
65. Waskiewicz AJ, Flynn A, Proud CG, Cooper JA. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2. EMBO J. 16(8), 1909-1920 (1997) (Pubitemid 27170952)
66. Alain T, Lun X, Martineau Y, et al. Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc. Natl Acad. Sci. USA 107(4), 1576-1581 (2010)
67. Pestova TV, Shatsky IN, Hellen CU. Functional dissection of eukaryotic initiation factor 4F: the 4A subunit and the central domain of the 4G subunit are sufficient to mediate internal entry of 43S preinitiation complexes. Mol. Cell. Biol. 16(12), 6870-6878 (1996) (Pubitemid 26389746)
68. Hundsdoerfer P, Thoma C, Hentze MW. Eukaryotic translation initiation factor 4GI and p97 promote cellular internal ribosome entry sequence-driven translation. Proc. Natl Acad. Sci. USA 102(38), 13421-13426 (2005) (Pubitemid 41420863)
69. Kaiser C, Dobrikova EY, Bradrick SS, Shveygert M, Herbert JT, Gromeier M. Activation of cap-independent translation by variant eukaryotic initiation factor 4G in vivo. RNA 14(10), 2170-2182 (2008)
70. Dephoure N, Zhou C, Villén J, et al. A quantitative atlas of mitotic phosphorylation. Proc. Natl Acad. Sci. USA 105(31), 10762-10767 (2008)
71. Raught B, Gingras A-C, Gygi SP, et al. Serum-stimulated, rapamycin-sensitive phosphorylation sites in the eukaryotic translation initiation factor 4GI. EMBO J. 19(3), 434-444 (2000) (Pubitemid 30072613)
72. Marintchev A, Edmonds KA, Marintcheva B, et al. Topology and regulation of the human eIF4A/4G/4H helicase complex in translation initiation. Cell 136(3), 447-460 (2009)
73. Dobrikov M, Dobrikova E, Shveygert M, Gromeier M. Phosphorylation of eIF4G1 by PKCa regulates eIF4G1 binding to Mnk1. Mol. Cell. Biol. 31(14), 2947-2959 (2010)
74. Svitkin YV, Herdy B, Costa-Mattioli M, Gingras A-C, Raught B, Sonenberg N. Eukaryotic translation initiation factor 4E availability controls the switch between cap-dependent and internal ribosomal entry site-mediated translation. Mol. Cell. Biol. 25(23), 10556-10565 (2005) (Pubitemid 41681976)
75. Haghighat A, Mader S, Pause A, Sonenberg N. Repression of cap-dependent translation by 4E-binding protein 1: competition with p220 for binding to eukaryotic initiation factor-4E. EMBO J. 14(22), 5701-5709 (1995)
76. Pause A, Belsham GJ, Gingras AC. Insulin-dependent stimulation of protein synthesis by phosphorylation of a regulator of 5′-cap function. Nature 371(6500), 762-767 (1994)
77. Beretta L, Gingras AC, Svitkin YV, Hall MN, Sonenberg N. Rapamycin blocks the phosphorylation of 4E-BP1 and inhibits cap-dependent initiation of translation. EMBO J. 15(3), 658-664 (1996) (Pubitemid 26044579)